• 1
    Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery. Gut 2005; 54: 23741.
  • 2
    Stange EF, Travis SP, Vermeire S, et al. European Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohn’s Colitis 2008; 2: 123.
  • 3
    Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut 2006; 55(Suppl. 1): i1635.
  • 4
    Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007; 1: CD000478.
  • 5
    Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev 2000; 2: CD000067.
  • 6
    Svartz N. Salazyopyrin, a new sulfanilamide preparation: A. Therapeutic results in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations in treatment with sulfanilamide preparation. Acta Med Scand 1942; 110: 55790.
  • 7
    Baron JH, Connell A, Lennard-Jones J, Jones F. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet 1962; 3: 10946.
  • 8
    Truelove SC, Watkinson G, Draper G. Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis. Br Med J 1962; 29: 170811.
  • 9
    Dick AP, Grayson MJ, Carpenter RG, Petrie A. Controlled trial of sulphasalazine in the treatment of ulcerative colitis. Gut 1964; 5: 43742.
  • 10
    Dissanayake AS, Truelove SC. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin). Gut 1973; 14: 9236.
  • 11
    Azad Khan AK, Howes DT, Piris J, Truelove SC. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut 1980; 21: 23240.
  • 12
    Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977; 2: 8925.
  • 13
    Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993; 118: 5409.
  • 14
    Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007; 5: 95102.
  • 15
    Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007; 132: 6675.
  • 16
    Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008; 57: 893902.
  • 17
    Kruis W, Gorelov A, Kiudelis G, et al. Once daily dosing of 3 g mesalamaine (Salofalk (R) granules) is therapeutic equivalent to a three-times daily dosing of ig mesalamine for the treatment of active ulcerative colitis. Gastroenterology 2008; 132: A1301.
  • 18
    Dignass A, Vermeire S, Adamek H, et al. Improved remission rates from once- versus twice-daily mesalazine (Pentasa) granules for the maintenance of remission in ulcerative colitis: results from a multinational randomised controlled trial [abstract]. Endoscopy 2007; 37: A467.
  • 19
    Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 57785.
  • 20
    Cross RK, Wilson KT, Binion DG. Polypharmacy and Crohn’s disease. Aliment Pharmacol Ther 2005; 21: 12116.
  • 21
    Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114: 3943.
  • 22
    Ediger JP, Walker JR, Graff L, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol 2007; 102: 141726.
    Direct Link:
  • 23
    Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126: 4519.
  • 24
    Velayos FS, Loftus EV Jr, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 2006; 130: 9419.
  • 25
    Van Staa TP, Card T, Logan RF, Leufkens HG. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 2005; 54: 15738.
  • 26
    Oldenburg B, Hommes D. Biological therapies in inflammatory bowel disease: top-down or bottom-up? Curr Opin Gastroenterol 2007; 23: 3959.
  • 27
    Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53(Suppl. 5): V116.
  • 28
    Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997; 92: 20411.
  • 29
    Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004; 99: 137185.
    Direct Link:
  • 30
    D’Haens G, Baert F, Van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 2008; 371: 6607.
  • 31
    Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006; 2: CD000544.
  • 32
    Bebb JR, Scott BB. How effective are the usual treatments for ulcerative colitis? Aliment Pharmacol Ther 2004; 20: 1439.
  • 33
    Hanauer SB. Review article: evolving concepts in treatment and disease modification in ulcerative colitis. Aliment Pharmacol Ther 2008; 27(Suppl. 1): 1521.
  • 34
    Egan LJ, Sandborn WJ. Advances in the treatment of Crohn’s disease. Gastroenterology 2004; 126: 157481.
  • 35
    Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s Disease. Cochrane Database Syst Rev 2005; 1: CD003715.
  • 36
    Steinhart AH, Forbes A, Mills EC, Rodgers-Gray BS, Travis SP. Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn’s disease. Aliment Pharmacol Ther 2007; 25: 138999.
  • 37
    Blomqvist P, Feltelius N, Lofberg R, Ekbom A. A 10-year survey of inflammatory bowel diseases-drug therapy, costs and adverse reactions. Aliment Pharmacol Ther 2001; 15: 47581.
  • 38
    Gearry RB, Ajlouni Y, Nandurkar S, Iser JH, Gibson PR. 5-Aminosalicylic acid (mesalazine) use in Crohn’s disease: a survey of the opinions and practice of Australian gastroenterologists. Inflamm Bowel Dis 2007; 13: 100915.
  • 39
    Ardizzone S, Maconi G, Sampietro GM, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn’s disease. Gastroenterology 2004; 127: 73040.
  • 40
    Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn’s disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004; 127: 7239.
  • 41
    Lemann M. Review article: can post-operative recurrence in Crohn’s disease be prevented? Aliment Pharmacol Ther 2006; 24(Suppl. 3): 228.
  • 42
    Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut 1995; 37: 6748.
  • 43
    Fernandez-Banares F, Bertran X, Esteve-Comas M, et al. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol 1996; 91: 24989.
  • 44
    Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease. Cochrane Database. Syst Rev 2000; 2: CD000545.
  • 45
    Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi PG. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006; 55: 4753.
  • 46
    Sandborn WJ, Tremaine WJ, Wolf DC, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn’s disease. North American Azathioprine Study Group. Gastroenterology 1999; 117: 52735.
  • 47
    Vind I, Riis L, Jess T, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003–2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol 2006; 101: 127482.
    Direct Link:
  • 48
    Campbell S, Ghosh S. Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy. Eur J Gastroenterol Hepatol 2001; 13: 1297301.
  • 49
    Mantzaris GJ, Sfakianakis M, Archavlis E, et al. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol 2004; 99: 11228.
    Direct Link:
  • 50
    Dewit O, Vanheuverzwyn R, Desager JP, Horsmans Y. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn’s disease. Aliment Pharmacol Ther 2002; 16: 7985.
  • 51
    Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995; 39: 4569.
  • 52
    Hande S, Wilson-Rich N, Bousvaros A, et al. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis 2006; 12: 2517.
  • 53
    Gilissen LP, Derijks LJ, Verhoeven HM, et al. Pancytopenia due to high 6-methylmercaptopurine levels in a 6-mercaptopurine treated patient with Crohn’s disease. Dig Liver Dis 2007; 39: 1826.
  • 54
    Lewis LD, Benin A, Szumlanski CL, et al. Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther 1997; 62: 46475.
  • 55
    Gilissen LP, Bierau J, Derijks LJ, et al. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. Aliment Pharmacol Ther 2005; 22: 60511.
  • 56
    Derijks LJ, Gilissen LP, Engels LG, et al. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit 2004; 26: 3118.
  • 57
    Derijks LJ, Gilissen LP, Hooymans PM, Hommes DW. Review article: thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther 2006; 24: 71529.
  • 58
    Lowry PW, Szumlanski CL, Weinshilboum RM, Sandborn WJ. Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction. Gastroenterology 1999; 116: 15056.
  • 59
    Lowry PW, Franklin CL, Weaver AL, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 2001; 49: 65664.
  • 60
    Bernal I, Domenech E, Garcia-Planella E, et al. Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Dig Dis Sci 2006; 51: 21659.
  • 61
    Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296310.
  • 62
    Crohn B, Rosenberg H. The sigmoidoscopic picture of chronic ulcerative colitis (non-specific). Am J Med Sci 1925; 170: 2207.
  • 63
    Gillen CD, Andrews HA, Prior P, Allan RN. Crohn’s disease and colorectal cancer. Gut 1994; 35: 6515.
  • 64
    Gillen CD, Walmsley RS, Prior P, Andrews HA, Allan RN. Ulcerative colitis and Crohn’s disease: a comparison of the colorectal cancer risk in extensive colitis. Gut 1994; 35: 15902.
  • 65
    Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 52635.
  • 66
    Langholz E, Munkholm P, Davidsen M, Binder V. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992; 103: 144451.
  • 67
    Jess T, Loftus EV Jr, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology 2006; 130: 103946.
  • 68
    Winther KV, Jess T, Langholz E, Munkholm P, Binder V. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2004; 2: 108895.
  • 69
    Lakatos L, Mester G, Erdelyi Z, et al. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis 2006; 12: 20511.
  • 70
    Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006; 130: 10308.
  • 71
    Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990; 323: 122833.
  • 72
    Gyde SN, Prior P, Allan RN, et al. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut 1988; 29: 20617.
  • 73
    Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease. Aliment Pharmacol Ther 2006; 23: 1097104.
  • 74
    Broome U, Lofberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995; 22: 14048.
  • 75
    Jess T, Loftus EV Jr, Velayos FS, et al. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol 2007; 102: 82936.
    Direct Link:
  • 76
    Velayos FS, Loftus EV Jr, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 2006; 130: 19419.
  • 77
    Bernstein CN, Blanchard JF, Metge C, Yogendran M. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol 2003; 98: 27848.
    Direct Link:
  • 78
    Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005; 100: 134553.
    Direct Link:
  • 79
    Boland CR, Luciani MG, Gasche C, Goel A. Infection, inflammation, and gastrointestinal cancer. Gut 2005; 54: 132131.
  • 80
    Strevel EL, Irvine EJSF, Steinhart AH. Immunosuppressives and surgery reduce risk of GI cancers in patients with Crohn’s disease: a case control study. Can J Gastroenterol 2005; 19(Suppl. B): 5B.
  • 81
    Gasche C, Goel A, Natarajan L, Boland CR. Mesalazine improves replication fidelity in cultured colorectal cells. Cancer Res 2005; 65: 39937.
  • 82
    Luciani MG, Campregher C, Fortune JM, Kunkel TA, Gasche C. 5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint. Gastroenterology 2007; 132: 22135.
  • 83
    Goel A, Nagasaka T, Gasche C, Boland CR. Chemopreventive effects of mesalazine through inhibition of DNA methyltransferases and reactivation of methylation-silenced genes in human colon cancer cells. Gastroenterology 2007; 1: A39.
  • 84
    Joshi R, Kumar S, Unnikrishnan M, Mukherjee T. Free radical scavenging reactions of sulfasalazine, 5-aminosalicylic acid and sulfapyridine: mechanistic aspects and antioxidant activity. Free Radic Res 2005; 39: 116372.
  • 85
    Bos CL, Diks SH, Hardwick JC, Walburg KV, Peppelenbosch MP, Richel DJ. Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity. Carcinogenesis 2006; 27: 237182.
  • 86
    Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 2005; 201: 120515.
  • 87
    Schwab M, Reynders V, Loitsch S, et al. PPAR{gamma} is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. Carcinogenesis 2008; 29: 140714.
  • 88
    Monteleone G, Franchi L, Fina D, et al. Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells. Cell Death Differ 2006; 13: 20211.
  • 89
    Reinacher-Schick A, Schoeneck A, Graeven U, Schwarte-Waldhoff I, Schmiegel W. Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells. Carcinogenesis 2003; 24: 44351.
  • 90
    Stolfi C, Fina D, Caruso R, et al. Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase. Carcinogenesis 2008; 29: 125866.